Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.
- NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_assertion description "[JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.
- NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_assertion evidence source_evidence_literature NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.
- NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_assertion SIO_000772 25189729 NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.
- NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_assertion wasDerivedFrom befree-2016 NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.
- NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_assertion wasGeneratedBy ECO_0000203 NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.
- befree-2016 importedOn "2016-02-19" NP1217009.RAkBe1RmJNg7h_N09pazt5QTALHVSWv2Uew9_ba796Dv0130_provenance.